Submit Deal

REPLIGEN CORPORATION

Summary

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs.

Deals Overview

Total Deals7

Valued Deals4

Total Value£ 502 M

Avg. Deal Size£ 125 M

Market Context

Senior Management

Olivier Loeillot
President and CEO
Tony J. Hunt
President and CEO
Jon K. Snodgres
CFO

Sort

jp morgan

HQ - New York

debt providers (1)

financial advisors (1)

2 Shared Deals

1 For | 1 Opposite

£ 185 M

Total Value

perella weinberg partners

HQ - New York

financial advisors (6)

6 Shared Deals

5 For | 1 Opposite

£ 502 M

Total Value

simpson thacher & bartlett

HQ - New York

legal advisors to debt providers (1)

1 Shared Deal

1 For

£ 185 M

Total Value

goodwin procter

HQ - Boston

legal advisors (6)

6 Shared Deals

6 For

£ 502 M

Total Value

arthur cox

HQ - Dublin, Ireland

legal advisors (1)

1 Shared Deal

1 For

£ 153 M

Total Value

covington & burling

HQ - Washington DC

legal advisors to financial advisors (1)

1 Shared Deal

1 For

£ 153 M

Total Value

ec m&a

financial advisors (3)

3 Shared Deals

1 For | 2 Opposite

£ 262 M

Total Value

enterprise counsel group

legal advisors (1)

1 Shared Deal

1 Opposite

£ 153 M

Total Value

peter taylor law

legal advisors (1)

1 Shared Deal

1 Opposite

£ 153 M

Total Value

morgan lewis & bockius

HQ - Philadelphia

legal advisors (1)

1 Shared Deal

1 Opposite

£ 108 M

Total Value

setterwalls advokatbyra

legal advisors (1)

1 Shared Deal

1 Opposite

n/a

Total Value

vinge

HQ - Stockholm

legal advisors (1)

1 Shared Deal

1 For

n/a

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy